Outcome of Cisplatin and Vinblastine Versus Paclitaxel and Carboplatin as Sequential Chemotherapy Followed by Radiotherapy in Locally Advanced Non-small Cell Lung Cancer

Lung cancer is the leading malignancy worldwide and in Bangladesh. Most of the lung cancer is of Non-small Cell Lung Cancer (NSCLC) type. For locally advanced NSCLC, combined modality treatment is required. Concurrent chemo-radiotherapy and sequential chemo-radiotherapy are the two recommended options. Sequential chemo-radiotherapy is mainly practiced in Bangladesh due to its less toxicity profile. There is no head to head comparative study done which focuses on the sequential chemotherapy regimens used in locally advanced NSCLC.

Hypothesis:

Null Hypothesis (H0): Sequential chemotherapy with cisplatin and vinblastine followed by radiotherapy and paclitaxel and carboplatin followed by the same radiotherapy in locally advanced NSCLC, there is no difference in loco-regional tumor control.

Alternative Hypothesis (HA): Sequential chemotherapy with cisplatin and vinblastine followed by radiotherapy and paclitaxel and carboplatin followed by the same radiotherapy in locally advanced NSCLC, cisplatin and vinblastine is more responsive and effective in loco-regional tumor control than paclitaxel and carboplatin.

Study Overview

• Status: Completed
• Conditions: Carcinoma, Non-Small-Cell Lung
• Intervention / Treatment: Drug: Paclitaxel; Drug: Carboplatin; Radiation: three dimensional conformal radiotherapy; Drug: Cisplatin; Drug: Vinblastine Sulfate

Detailed Description

Lung cancer is the leading malignancy worldwide and in Bangladesh. Most of the lung cancer is of Non-small Cell Lung Cancer (NSCLC) type. For locally advanced NSCLC, combined modality treatment is required. Concurrent chemo-radiotherapy and sequential chemo-radiotherapy are the two recommended options. Sequential chemo-radiotherapy is mainly practiced in Bangladesh due to its less toxicity profile. There is no head to head comparative study done which focuses on the sequential chemotherapy regimens used in locally advanced NSCLC.

Aim and Objective:

To compare treatment outcome and acute toxicities between two standard sequential chemotherapy regimens (Cisplatin and Vinblastine followed by radiotherapy and Paclitaxel and Carboplatin followed by same radiotherapy) in patients with locally advanced stage III NSCLC.

Material and Method:

A total number of 60 patients, who are clinically locally advanced (stage III A and III B), histologically proven NSCLC, inoperable and with ECOG performance score upto grade 2 and body weight loss <10 % in 3 months will be included in this study.

Patients will be randomly assigned to receive either Arm A or Arm B. Arm A will receive - paclitaxel 200 mg/m2 body surface area(BSA) i.v over 3 hrs on D1; carboplatin Area Under Curve(AUC) 6 i.v over 60 minutes on D1 every 3 wks for 2 cycles followed by radiotherapy with 6000 (Centigray)c Gy given in 30 fractions beginning on day 42 And Arm B will receive - cisplatin (100 mg/m2 BSA i.v over 2 hrs. on days 1 and 29) and vinblastine (5 mg/m2 BSA i.v rapidly push weekly on days 1,8,15,22 and 29) followed by radiotherapy with 6000 cGy given in 30 fractions beginning on day 50 .

All patients will be followed up as per guideline for 6 months in this study. Discussion: All the relevant data will be compiled on a master chart first and then statistical analysis of the results will be obtained by using Window based computer software devised with Statistical Packages for Social Sciences (SPSS-17) (SPSS Inc, Chicago Illinois(IL) USA). The data will be analyzed using Chi-square test and 'T' test and association will be analyzed by Pearson's correlation coefficient (r value) test. The results will be presented in tables, figures, diagrams. Significant value of 'p' will be decided at a level of 0.05 in two tailed tests.

Selection of patients:

A. Inclusion Criteria:

• Patients with locally advanced (stage III a, b) NSCLC.
• Patients who are inoperable. Patients Eastern Co-operative Group (ECOG) performance score up to grade 2.

B. Exclusion Criteria:

• Age below 18 years.
• Patients with history of prior chemotherapy or radiotherapy to lung region.
• Serious concomitant medical illness including severe heart disease, uncontrolled diabetes mellitus or hypertension.
• Life expectancy < 6 months.
• Patient with uncontrolled infection
• Pregnant or lactating woman.
• Psychiatric illness.

Minimum laboratory criteria required to include:

• Hemoglobin should be more than 10 gm. /dl or more than 60%.
• An absolute white blood count(WBC) more than or equal to 4000 cells/mm3.
• Platelet count more than or equal to 100000 cells/mm3.
• Bilirubin level should be equal to or less than 1.5 mg/dl.
• SGPT(serum glutamic-pyruvic transaminase) level not more than 4 times of the upper limit.
• Serum creatinine level should be equal to or less than 1.5 mg/dl.
• Blood Urea level less than 50 mg/dl. Sampling technique Randomized number generator, a random number generator is a computational process that produces random numbers by using statistical algorithm.

Outcome measures:

table- clinical response , a 3rd follow up at week 30 after completion of treatment for both the arms (n=60)

response Arm A Arm B X2 value P value Complete response (CR) Partial response (PR) Progressive disease (PD) Stable disease (SD)

Responses Description Complete Response ( CR ) Disappearance of all known diseases, confirmed at ≥ 4 weeks Partial Response ( PR ) ≥ 50 % decrease from baseline, confirmed at ≥ 4 weeks.

Progressive disease ( PD ) ≥ 25 % increase in one or more lesions or appearance of new lesions Stable disease ( SD ) Neither PR or PD criteria met

• Study Type: Interventional
• Enrollment (Actual): 60
• Phase: Phase 4

Contacts and Locations

Study Locations

• Bangladesh
  • Dhaka, Bangladesh, 1000
    • Department of Oncology,Bangabandhu Sheikh Mujib Medical university

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: ADULT; OLDER_ADULT; CHILD
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• • Patients with locally advanced (stage III a, b) non-small cell lung cancer.

  • Patients who are inoperable. Patients Eastern Co-operative Group (ECOG) performance score up to grade 2.

Exclusion Criteria:

• • Age below 18 years.

  • Patients with history of prior chemotherapy or radiotherapy to lung region.
  • Serious concomitant medical illness including severe heart disease, uncontrolled diabetes mellitus or hypertension.
  • Life expectancy < 6 months.
  • Patient with uncontrolled infection
  • Pregnant or lactating woman.
  • Psychiatric illness.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: NONE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
ACTIVE_COMPARATOR: chemotherapy with paclitaxel and carboplatin; Intervention: paclitaxel 200 mg/m2 AUC and carboplatin AUC 6 on day 1 every 3 wks for 2 cycles followed by three dimensional conformal radiotherapy on day 42	Drug: Paclitaxel; paclitaxel 200 mg/m2 i.v over 3 hrs on day 1, every 21 days for 2 cycles followed by radiotherapy on day 42; Other Names: Xelpac; Drug: Carboplatin; carboplatin AUC 6 iv over 1 hr on day 1 , every 212 days for 2 cycle followed by radiotherapy on day 42; Other Names: carboplat; Radiation: three dimensional conformal radiotherapy; three dimensional conformal radiotherapy would be given at day 42 after completion of paclitaxel and carboplatin 2 cycle and at day 50 after completion of cisplatin and vinblastin from d1 to d29
EXPERIMENTAL: chemotherapy with cisplatin and vinblastine; Intervention : cisplatin 100 mg/m2 on day 1 and 29 and vinblastine 5mg/m2 on days 1,8,15,22 and 29 followed by three dimensional conformal radiotherapy on day 50	Radiation: three dimensional conformal radiotherapy; three dimensional conformal radiotherapy would be given at day 42 after completion of paclitaxel and carboplatin 2 cycle and at day 50 after completion of cisplatin and vinblastin from d1 to d29; Drug: Cisplatin; cisplatin 100 mg/m2 i.v over 2 hrs on day 1 and 29 followed by radiotherapy on day 50; Other Names: Platinex; Drug: Vinblastine Sulfate; Vinblastin 5mg/m2 i.v on day 1,8,15,22 and 29 followed by radiotherapy on day 50; Other Names: Velvin

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
tumor response	complete response(CR), partial response(PR), progressive disease(PD) and stable disease(SD),Responses Description Complete Response ( CR ) Disappearance of all known diseases, confirmed at ≥ 4 weeks. Partial Response ( PR ) ≥ 50 % decrease from baseline, confirmed at ≥ 4 weeks. Progressive disease ( PD ) ≥ 25 % increase in one or more lesions or appearance of new lesions Stable disease ( SD ) Neither PR or PD criteria met final tumor response will be seen in 30 weeks of starting of completion and will be considered as the primary outcome	30 weeks

Collaborators and Investigators

• Sponsor: Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

Study record dates

Study Major Dates

• Study Start (ACTUAL): January 1, 2017
• Primary Completion (ACTUAL): June 1, 2018
• Study Completion (ACTUAL): December 1, 2018

Study Registration Dates

• First Submitted: March 22, 2017
• First Submitted That Met QC Criteria: March 22, 2017
• First Posted (ACTUAL): March 28, 2017

Study Record Updates

• Last Update Posted (ACTUAL): March 8, 2019
• Last Update Submitted That Met QC Criteria: March 6, 2019
• Last Verified: March 1, 2019

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Respiratory Tract Diseases; Neoplasms; Lung Diseases; Neoplasms by Site; Respiratory Tract Neoplasms; Thoracic Neoplasms; Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Molecular Mechanisms of Pharmacological Action; Antineoplastic Agents; Tubulin Modulators; Antimitotic Agents; Mitosis Modulators; Antineoplastic Agents, Phytogenic; Carboplatin; Paclitaxel; Cisplatin; Vinblastine
• Other Study ID Numbers: BangabandhuONCOLOGY

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No